Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial in the U.S., evaluating the safety, ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

The only thing more awkward than forgetting your kid? Finding him Home Alone with two corpses.

AN ENLIGHTENING session, entitled ‘Emerging therapeutic frontiers in cardiology: what does the future hold?’, delivered at ...

Chronic liver inflammation is one of the most serious complications associated with liver cirrhosis. Researchers from Miguel Hernández University of Elche (UMH) in Spain have identified a molecular ...

Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry ...

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE.

AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ...

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the ...